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Abstract
Background: Long-lived strains of dwarf mice carry mutations that suppress growth hormone
(GH) and insulin-like growth factor I (IGF-I) signaling. The downstream effects of these endocrine
abnormalities, however, are not well understood and it is unclear how these processes interact
with aging mechanisms. This study presents a comparative analysis of microarray experiments that
have measured hepatic gene expression levels in long-lived strains carrying one of four mutations
(Prop1df/df, Pit1dw/dw, Ghrhrlit/lit, GHR-KO) and describes how the effects of these mutations relate to
one another at the transcriptional level. Points of overlap with the effects of calorie restriction
(CR), CR mimetic compounds, low fat diets, gender dimorphism and aging were also examined.
Results: All dwarf mutations had larger and more consistent effects on IGF-I expression than
dietary treatments. In comparison to dwarf mutations, however, the transcriptional effects of CR
(and some CR mimetics) overlapped more strongly with those of aging. Surprisingly, the Ghrhrlit/lit
mutation had much larger effects on gene expression than the GHR-KO mutation, even though both
mutations affect the same endocrine pathway. Several genes potentially regulated or co-regulated
with the IGF-I transcript in liver tissue were identified, including a DNA repair gene (Snm1) that is
upregulated in proportion to IGF-I inhibition. A total of 13 genes exhibiting parallel differential
expression patterns among all four strains of long-lived dwarf mice were identified, in addition to
30 genes with matching differential expression patterns in multiple long-lived dwarf strains and
under CR.
Conclusion: Comparative analysis of microarray datasets can identify patterns and consistencies
not discernable from any one dataset individually. This study implements new analytical approaches
to provide a detailed comparison among the effects of life-extending mutations, dietary treatments,
gender and aging. This comparison provides insight into a broad range of issues relevant to the
study of mammalian aging. In this context, 43 longevity-associated genes are identified and individual
genes with the highest level of support among all microarray experiments are highlighted. These
results provide promising targets for future experimental investigation as well as potential clues for
understanding the functional basis of lifespan extension in mammalian systems.
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Background
Long-lived dwarf strains of laboratory mice offer promis-
ing tools for advancing our understanding of aging mech-
anisms and the basis of extended lifespan in mammals.
Dwarf models have been found to exhibit an average
lifespan increase of more than 50% compared to wildtype
control strains, and thus represent genetic manipulations
with an impact on longevity that is comparable to calorie
restricted diets [1]. In addition to lifespan extension, long-
lived dwarf strains exhibit superior health at advanced
ages [2], and are less susceptible to age-related declines in
memory, learning ability, and locomotion [3]. Dwarf
mice experience lower incidence of kidney disease, cata-
racts and joint disease, as well as fatal neoplastic disease,
such as lymphoma and adenocarcinoma [4-6]. Earlier
studies have also suggested that development of trans-
planted tumors is impeded in dwarf mice, and cancer rates
are reduced following exposure to chemical carcinogens
[7,8]. The loss of immune function and progression of
collagen cross-linking that normally occurs with advanc-
ing age is diminished in some dwarf strains [9], and at the
cellular level, fibroblasts of dwarf mice are resistant to sev-
eral forms of stress, including oxidative stress, ultraviolet
light, toxic metals and heat [10,11]. Aside from improving
our knowledge of aging mechanisms, therefore, under-
standing the unique features of dwarf mice may provide
insight into a broad range of mechanisms relevant to
health and disease-prevention in mammals.
Long-lived dwarf mouse strains carry mutations that sup-
press the growth hormone (GH)/insulin-like growth fac-
tor I (IGF-I) endocrine pathway [1]. In Ames (Prop-1df/df)
and Snell (Pit-1dw/dw) mutants, for instance, development
of the anterior pituitary is inhibited completely. This
results in reduced GH and IGF-I levels, as well as other
hormonal abnormalities, such as deficiency of thyroid
stimulating hormone and prolactin [12,13]. Ames and
Snell dwarfs exhibit considerably reduced body size, but
also have dramatic lifespan extension of 40–69% on aver-
age. In the Little (Ghrhrlit/lit) mouse, lifespan extension is
less substantial (23–25%), and only occurs when mice are
provided a low fat diet [9]. Hormonal abnormality of Lit-
tle mice is limited to circulating GH levels, which are
reduced because the lit/lit mutation renders the pituitary
unresponsive to GH releasing hormone [14]. It is some-
what surprising that genetic alterations downstream of the
lit/lit  mutation promote a larger lifespan increase than
that observed in little mice. In particular, GH-receptor
knock-out mice (GHR-KO) have elevated serum GH lev-
els, but are growth hormone resistant and exhibit consid-
erable lifespan increases of 38–55% on average [15].
Taken together, these findings from four long-lived dwarf
models firmly establish an endocrine basis of lifespan
extension in mammals. Nevertheless, it remains unclear
why such endocrine abnormalities affect lifespan, since
inhibition of GH/IGF-I signaling is associated with exten-
sive downstream effects, and only a fraction of these
effects may be linked to mechanisms of aging [16].
Identification of genes affected by GH and IGF-I suppres-
sion is an important step towards understanding how this
axis impacts longevity. Microarray studies of long-lived
dwarf mice have been especially useful in this regard [17-
20]. Previous studies have focused primarily on liver tis-
sue, since this is the major manufacturing site of IGF-I.
Early investigations used cDNA arrays to detect expression
differences between dwarf and normal mice, and found
that 13 of 265 surveyed transcripts (4.9%) were differen-
tially expressed in Ames dwarfs [17], while 60 of 2352
(2.5%) surveyed transcripts were differentially expressed
in the Snell model [18]. Subsequent studies have used
Affymetrix oligonucleotide arrays to screen a larger frac-
tion of the genome. For instance, Amador-Noguez et al.
[19] found that approximately 1100 of 14-thousand
Affymetrix probesets (8.1%) were differentially expressed
in Ames and Little dwarfs, respectively, while 547 (4.0%)
transcripts were differentially expressed in both models.
Boyleston et al. [20] performed a similar study using Ames
and Snell dwarf mice, but focused only on probesets dif-
ferentially expressed at every age group examined (6 – 24
months). This approach highlighted 785 such probesets
in the Ames dwarf (1.9% of those surveyed), along with
205 probesets (1.7%) in the Snell dwarf, with 49
probesets satisfying the criterion in both long-lived mod-
els.
Previous microarray studies of long-lived dwarf mice have
used varying statistical methodologies and criteria for
identifying candidate genes, which complicates compari-
sons among studies based upon published results. Such
comparisons would be useful, since genes differentially
expressed with respect to multiple long-lived dwarf mod-
els are especially likely to play a role in aging and lifespan
determination [17,18]. Endocrine abnormalities differ to
some degree among dwarf models, but presumably,
lifespan extension in each model results from shared alter-
ations that affect the GH/IGF-I pathway. Genes underly-
ing extended lifespan should therefore be identified with
respect to all long-lived models, while genes involved in
pathways unrelated to lifespan extension should be spe-
cific to particular models. Furthermore, from a statistical
perspective, a fraction of genes identified with respect to
any one long-lived model in a single study are expected to
be false-positives [21]. However, since P-values combine
multiplicatively when results are pooled across studies
[22], genes differentially expressed in more than one
study are less likely to be false positive identifications.
From biological and statistical standpoints, therefore, it is
desirable to utilize data from independent studies to iden-BMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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tify genes commonly induced among multiple long-lived
dwarf models.
This study presents a comparative analysis of microarray
experiments that have examined hepatic gene expression
differences between long-lived dwarf mice and normal
controls. The results provide a detailed view of how the
effects of different dwarf mutations relate to one another
in terms of gene expression, and describe how these
effects relate to those associated with aging, gender dimor-
phism, low fat diets, caloric restriction (CR) and several
different CR mimetic compounds. A main goal of the
analysis was to identify longevity-associated genes with
the highest level of support based on currently available
microarray data. Applying consistent statistical methodol-
ogy, therefore, genes exhibiting parallel differential
expression patterns in four long-lived dwarf models were
identified (Ames, Snell, Little and GHR-KO). Since mech-
anisms of lifespan extension in long-lived dwarf models
may overlap with those conferring increased longevity
under CR [23-25], genes exhibiting parallel transcrip-
tional changes in multiple long-lived models and under
CR were also identified. Further steps were taken to evalu-
ate the role of each candidate gene with respect to aging
and longevity, and to determine which genes provided the
most promise for future experimental investigation.
Results
Datasets and IGF-I expression patterns
Expression data was examined from four dwarf models
that have previously been associated with significant
lifespan extension in laboratory studies, including the
Ames (Prop1df/df), Snell (Pit1dw/dw), Little (Ghrhrlit/lit), and
GHR-KO (GHR-KO) mutants. Genetic alterations with
effects potentially related to those of life-extending dwarf
mutations were also considered. For instance, the effects
of two GHR knock-in models with disruptions of GHR
receptor residues 391 or 569 were examined [26]. Gene
expression levels of the B6.C3H-6T congenic mouse were
considered because this model exhibits a 30–40% reduc-
tion in serum IGF-I levels [27]. The effects of gender were
examined because female mice live longer than male
mice, and also because one study has suggested that dwarf
mutations induce a masculine-to-feminine shift in gene
expression patterns [20]. Dietary treatments known or
postulated to increase lifespan were considered for the
purpose of comparison. These treatments included low fat
diets, CR and several potential CR mimetic compounds
(metformin, glipizide, rosiglitazone, and soy isoflavone
extract). The potential CR mimetic compounds are known
to either influence insulin sensitivity (metformin, glipiz-
ide, rosiglitazone) or suppress tumorigenesis (soy isofla-
vone extract) [28]. Metformin treatment of female mice
has been found to increase mean and maximum lifespan
by 8% and 13%, respectively [29].
The analysis is based on a series of contrasts comparing
gene expression levels between two experimental treat-
ments. Table 1 provides descriptions and representative
symbols for all contrasts examined. Each contrast
involved a pair of treatments designated A and B. The A
treatment is a genotype or dietary manipulation known or
postulated to be associated with increased longevity. The
corresponding B treatment is an appropriate control that
permitted evaluation of how treatment A  affects gene
expression. The analysis was based on 8525 probesets that
could be reliably matched among all three platforms
(using Affymetrix best match tables). For each contrast,
the null hypothesis of H0: µAi = µBi was tested for each
probeset, where µAi and µBi represent the mean expression
levels of gene i in treatments A and B, respectively (see
Methods).
The Snell, Ames and Little dwarf mutants were associated
with large affects on gene expression at every age exam-
ined. Of 8525 probesets, the total number of genes differ-
entially expressed with respect to these dwarf mutants
ranged from 151 (contrast snell25) to as many as 987
(contrast ames3b) (see Table 2). IGF-I expression was sig-
nificantly downregulated in all contrasts involving the
Snell, Ames and Little dwarfs (Fig. 1, Table 2). IGF-I sup-
pression, however, may account for only a small fraction
of genes differentially expressed in these models. This is
because GHR-KO mice exhibited significant IGF-I tran-
script downregulation of larger magnitude than that
observed in the Snell, Ames and Little models, but never-
theless, only 46 genes exhibited differential expression in
GHR-KO mice (see Table 2). This suggests that a relatively
small number of genes may be specifically affected by IGF-
I suppression in mouse liver. It is interesting to note,
moreover, that IGF-I transcript levels are significantly
downregulated with respect to the GHR-KI2 contrast, but
not with respect to the GHR-KI1 contrast (Fig. 1, Table 2).
This difference is most likely attributable to the STAT5 sig-
naling pathway (signal transducer and activator of tran-
scriptions 5) downstream of GHR. GHR-KI1 mice lack
GHR residue 569, but exhibit only slight loss of hepatic
IGF-1 transcript because STAT5 signaling is partially func-
tional [26]. GHR-KI2 mice, however, lack GHR residue
391 and have no STAT5 signaling capacity, resulting in
substantial loss of IGF-1 transcript in liver [26].
IGF-I expression was far more sensitive to the dwarf muta-
tions than any of the dietary treatments examined, includ-
ing CR (see Fig. 1). IGF-I was significantly downregulated
in all contrasts involving dwarf mutants, but only one of
four CR treatments resulted in significant IGF-I downreg-
ulation [contrast cr(2,6)df]. For all other dietary treat-
ments, such as low fat diets and CR mimetics, IGF-I
transcript levels were not significantly affected, and in fact,
were slightly upregulated in most cases (Fig. 1, Table 2).B
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Table 1: Treatment Contrasts
Contrast Symbol Treatment A Treatment B
snell5a Pit1dw/dw males, age 4–6 months, n = 4 Pit1dw/? control males, age 4–6 months, n = 4
snell25a Pit1dw/dw males, age 24–26 months, n = 3 Pit1dw/? control males, age 24–26 months, n = 3
ames5Ab Prop1df/df males, age 4–6 months, n = 5 Prop1+/+ control males, age 4–6 months, n = 5
ames13Ab Prop1df/df males, age 12–14 months, n = 5 Prop1+/+ control males, age 12–14 months, n = 5
ames25Ab Prop1df/df males, age 24–27 months, n = 5 Prop1+/+ control males, age 24–27 months, n = 5
ames3Bc Prop1df/df males, age 3 months, n = 3 Prop1+/+ control males, age 3 months, n = 5
ames6Bc Prop1df/df males, age 6 months, n = 3 Prop1+/+ control males, age 6 months, n = 5
ames12Bc Prop1df/df males, age 12 months, n = 3 Prop1+/+ control males, age 12 months, n = 5
ames24Bc Prop1df/df males, age 24 months, n = 3 Prop1+/+ control males, age 24 months, n = 5
little3c Ghrhrlit/lit males, age 3 months, n = 3 Ghrhrlit/+ males, age 3 months, n = 3
little6c Ghrhrlit/lit males, age 6 months, n = 3 Ghrhrlit/+ males, age 6 months, n = 3
little12c Ghrhrlit/lit males, age 12 months, n = 3 Ghrhrlit/+ males, age 12 months, n = 3
little24c Ghrhrlit/lit males, age 24 months, n = 3 Ghrhrlit/+ males, age 24 months, n = 3
GHR-KOd GHR(-/-) males, age 42 days, n = 3 wild type males, age 42 days, n = 3
GHR-KI1d GHR knock-in mutant 569, males, age 42 days, n = 3 wild type males, age 42 days, n = 3
GHR-KI2d GHR knock-in mutant 391, males, age 42 days, n = 3 wild type males, age 42 days, n = 3
B6e C57BL/6J (B6) females, age 2 months, n = 3 (20–30% reduced serum IGF-I) C3H/HeJ (C3H) females, age 2 months, n = 3
Genderf wild type females, age 3–6 months, n = 6 wild type males, age 3–6 months, n = 6
cr(2,6)g 4 months of 30% calorie restriction, initiated age 2, tissue harvest age 6, wild type females, n = 8 wild type littermates of treatment A fed on control diet, n = 7
cr(2,6)dfg 4 months of 30% calorie restriction, initiated age 2, tissue harvest age 6, Prop1df/df females, n = 8 Prop1df/df female littermates of treatment A with control diet, n = 8
cr(20,22)h 2 months of 40% calorie restriction, initiated age 20, tissue harvest age 22, strain B6C3F1 males, n = 4 strain B6C3F1 males fed on control diet, tissue harvest age 22, n = 4
cr(5,22)h 17 months 40% calorie restriction, initiated age 5, tissue harvest age 22, strain B6C3F1 males, n = 4 strain B6C3F1 males fed on control diet, tissue harvest age 22, n = 4
meth metformin, 2100 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
met(db/db)i metformin, 400 mg/kg, C57BL/ksj – db/db males, n = 5 placebo, C57BL/ksj – db/db males, n = 5
gliph glipizide, 1050 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
gmh metformin & glipizide, met dose: 1050 mg per kg diet, glip dose: 525 mg per kg diet, tissue harvest age 22, 
strain B6C3F1 males, n = 4
control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
rosh rosiglitazone, 80 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
soyh soy isoflavone extract, 0.25%, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
lowfat1j 4.5% fat diet by weight, congenic C57BL/6J males, n = 3 21% fat diet by weight, congenic C57BL/6J males, n = 3
lowfat2k very low fat diet, strain C57BL/6J males, n = 5 normal diet, strain C57BL/6J males, n = 5
agel age 4 months, wild type, n = 4 age 32 months, wild type, n = 4
Each contrast corresponds to a test of differential expression and set of genes identified as significantly upregulated or downregulated. The A column lists treatments known or hypothesized to be 
associated with increased lifespan. The B column lists comparable control treatments associated with normal lifespan. All contrasts were of the form A – B, such that upregulated genes exhibit 
increased expression in treatment A (relative to treatment B) while downregulated genes exhibit decreased expression in treatment A (relative to treatment B). The RNA source for all treatments 
was liver and the value n refers to the number of independent biological replicates available for each treatment.
aGSE3129, MG-U74Av2, Boyleston et al. [20]
bGSE3150, MG 430 2.0, Boyleston et al. [20]
cEMEXP153, MOE 430A, Amador-Noguez et al. [19]
dGSE988, MG-U74Av2, Rowland et al. [26]
eGSE5959, MG-U74Av2, Adamo et al. [27]
fEMEXP347, MOE 430A, Amador-Noguez et al. [87]
gGSE1093, MG-U74Av2, Tsuchiya et al. [24]
hGSE2431, MG-U74Av2, Dhahbi et al. [28]
iEMEXP490, MG-U74Av2, Heishi et al. [88]
jGSE363, MG-U74Av2, Recinos et al. [89]
kGSE3889, MG 430 2.0, Flowers et al. [90]
lEMEXP839, MG 430 2.0, Niedernhofer et al. [91]BMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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Several genes exhibited expression patterns among all
contrasts that were positively or negatively related to IGF-
I expression (Fig. 2 and Additional files 1 and 2). These
genes are potentially regulated by or coregulated with the
IGF-I transcript in mouse liver tissue.
Differential expression signatures
The differential expression signature associated with a given
contrast was determined by testing H0: µAi = µBi for all i =
1,..., 8525 probesets included in the analysis. Genes for
which H0: µAi = µBi was not rejected were assigned a score
of 0. Genes for which H0:  µAi =  µBi was rejected were
assigned a score of ± 1, depending on whether the gene
was upregulated (mean expression higher in treatment A
relative to B) or downregulated (mean expression lower in
treatment A relative to B). The pattern of 0, 1, and -1
scores among all i = 1, .., 8525 genes defined the differen-
tial expression signature of each contrast.
Three of the four dwarf mutants (Snell, Ames, Little) were
associated with similar differential expression signatures
(Fig. 3). While the GHR-KO mutation was associated with
only a small number of transcriptional changes, most of
these changes were also found in the other three long-
lived models (Fig. 3). This similarity among long-lived
models is reflected by a hierarchical cluster analysis of dif-
ferential expression signatures (see Methods). All signa-
tures associated with long-lived dwarf models clustered
together in a single branch, and sub-branches within this
single branch are joined at high levels of similarity (see
Fig. 4). Dietary treatments, on the other hand, clustered
together at lower levels of similarity and in some cases
were placed in separate branches. It is noteworthy, for
instance, that signatures associated with contrasts
cr(2,6)df and cr(2,6) clustered in a branch apart from the
signatures of cr(5,22) and cr(20,22). This reflects the
degree to which the affect of CR on gene expression
Table 2: Overview of Differential Expression Results
Contrast Symbol IGF1 [log2(FC)] Upregulated Downregulated
snell5 -3.96* 129 187
snell25 -3.91* 65 86
ames4A -3.20* 347 273
ames10A -3.05* 314 214
ames22A -1.55* 229 171
ames3B -3.79* 567 420
ames6B -3.18* 501 470
ames12B -2.92* 424 307
ames24B -1.03* 305 193
little3 -2.46* 359 291
little6 -2.54* 328 314
little12 -2.23* 200 310
little24 -1.99* 206 269
GHR-KO -4.68* 8 38
GHR-KI1 -0.40 5 5
GHR-KI2 -5.29* 24 13
B6 -0.28 1 7
Gender 0.05 243 284
cr(2, 6) -0.08 93 67
cr(2, 6)df -0.85* 22 24
cr(20, 22) 0.26 65 116
cr(5, 22) 0.49 279 529
met 0.24 127 172
met (db/db) 0.20 166 523
glip 0.03 80 49
gm 0.32 114 107
ros 0.11 51 65
soy 0.17 45 32
lowfat1 0.20 6 8
lowfat2 -0.31 96 54
age 0.20 494 458
For each contrast, the number of probesets significantly upregulated and downregulated at a significance level of 0.05 is listed. The log-transformed 
fold-change [log2(FC)] associated with the insulin-like growth factor I (IGF1) transcript is also listed.
*test for differential expression significant with P < 0.05BMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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depends on how CR was carried out and, more particu-
larly, on the age at which necropsies are performed.
There were many cases in which the similarity between
signatures associated with two different contrasts was sig-
nificantly greater than expected on the basis of chance
(Fig. 5) (see Methods). This was generally true with regard
to comparisons between any two dwarf mutation con-
trasts (e.g., snell5 vs. little3), but was less often the case
with respect to comparisons between any two dietary
treatments (e.g., ros vs. lowfat1). For every contrast, how-
ever, there was some evidence that its signature over-
lapped significantly with that of at least one other contrast
(Fig. 5). The effects of gender overlapped significantly
with those of the dwarf mutations as well as the four CR
treatments. Additionally, differential expression signa-
tures associated with lowfat diet treatments were signifi-
cantly similar to those of dwarf mutations (especially the
Ghrhrlit/lit mutation) and multiple CR treatments (see Fig.
5).
The "age" contrast provides an indication of how young
livers (4 months) differ from aged livers (32 months) at
the gene expression level. Genetic alterations or dietary
manipulations with signatures similar to that of the age
contrast can be viewed as inducing a "reversal" of the
IGF-I expression Figure 1
IGF-I expression. The vertical axis corresponds to log-transformed gene expression values. The 31 contrasts listed in Table 
1 are ordered along the horizontal axis. Red circles correspond to expression values of replicate observations associated with 
the A treatment of each contrast, while black diamonds indicate replicate expression values associated with the control B treat-
ment of each contrast (see Table 1).
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aging process, at least insofar as gene expression levels in
mouse liver are concerned. From Figure 3, it is clear that
the age signature has fairly weak overlap with those of
other contrasts. Overall, however, the age signature clus-
ters together with dietary manipulations in a branch that
includes CR and CR mimetic compounds (Fig. 3). This
suggests that, in comparison to the dwarf mutations, the
effects of CR and some CR mimetics more closely resem-
ble a shift of the liver transcriptome towards a youthful
state. Additionally, whereas the differential expression sig-
nature of the age contrast was significantly similar to those
of some CR treatments, this wasn't the case for any con-
trasts involving dwarf mutants (see Fig. 5).
Longevity-associated genes I: long-lived dwarf mutants
A total of 13 genes were differentially expressed with
respect to all four long-lived mouse models (Fig. 6). Most
of these genes (10/13) were downregulated with respect
Potential IGF-I regulated or co-regulated genes Figure 2
Potential IGF-I regulated or co-regulated genes. The vertical axis corresponds to log-transformed fold-change. The 31 
contrasts listed in Table 1 are ordered along the horizontal axis. The thick black line represents fold-changes associated with 
IGF-I across the 31 contrasts. Red lines represent five genes for which fold-changes across contrasts are most positively asso-
ciated with those of IGF-I (Mup3, Es31, Igfals, Keg1, Socs2). Green lines represent five genes for which fold-changes across 
contrasts are most negatively associated with those of IGF-I (Scd2, Slc16a7, Pcp4l1, Snm1, Igfbp1). Additional files 1 and 2 pro-
vide plots for the top 40 genes most positively and negatively associated with the IGF-I expression pattern among all contrasts.
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to all four models, while only three genes were upregu-
lated (Hao3, Sult2a2, Spink3). Six of the identified genes
are localized to extracellular space, which is a significantly
unlikely result based on gene ontology cellular compo-
nent analysis (P < 0.01). Within the extracellular space,
these six genes influence in a diversity of processes,
including protein binding and transport (Mup4, Spink3),
signaling pathways that regulate cell proliferation (Igf1,
Lifr, Igfals) and detoxification (Es31). Significantly over-
represented biological process gene ontology terms
included steroid metabolism, positive regulation of cell
proliferation, positive regulation of cellular process,
enzyme linked receptor protein signaling pathway, elec-
tron transport, and cellular morphogenesis (P < 0.05).
The molecular function gene ontologies pheromone
binding and oxiodreductase activity (acting on CH-OH
group of donors) were also significantly overrepresented
(P < 0.01).
Williams et al. [30] have recently reported on baseline
expression levels of liver organs from 31 BxD mouse
strains (GEO Series GSE6621). The lifespan of 21 of these
Differential Expression Signatures Figure 3
Differential Expression Signatures. Each row corresponds to one of the contrasts listed in Table 1. Each column corre-
sponds to one of 2192 genes differentially expressed with respect to more than one contrast. Rows have been ordered to cor-
respond to the dendrogram shown in Figure 4. Red coloring indicates that a gene is upregulated (P < 0.05), while green 
coloring indicates that a gene is downregulated (P < 0.05).
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strains had previously been measured by Gelman et al.
[31]. Using these two data sources, the relationship
between expression levels of candidate genes and mean
lifespan across BxD mouse strains was examined (Fig. 7).
This analysis provided some slight, though non-signifi-
cant, additional support for a role of Hao3 in lifespan
determination (Fig. 7a). Hao3 is a peroxisome-targeted
hydroxyacid oxidase [32], and was significantly upregu-
lated with respect to all four long-lived dwarf models.
Correspondingly, long-lived BxD strains exhibited higher
Hao3 expression (rs = 0.366). Taken alone, this correlation
was marginally significant (P = 0.051), but was non-sign-
ficant following Benjamini-Hochberg adjustments for
multiple testing (P = 0.322).
Longevity-associated genes II: dwarf mutants and CR
The same mechanisms underlying extended lifespan in
dwarf mutants may contribute to the longevity extension
that results from CR [23-25]. Of genes differentially
expressed in all four long-lived models, only three were
also differentially expressed with respect to at least one CR
contrast (Igf1, Igfals and Lifr) (Fig. 6). To the extent that
longevity extension in dwarf mutants has a common basis
with longevity extension by CR, these three genes are the
Hierarchical cluster analysis Figure 4
Hierarchical cluster analysis. Each branch corresponds to a differential expression signature shown in Figure 3. The hori-
zontal axis indicates the average level of similarity at which two clusters were joined (see Equation 1 in Methods).
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most well supported longevity-associated genes identified
by this analysis.
Previous criteria was altered to obtain an expanded list of
gene candidates that are differentially expressed with
respect to long-lived dwarf models and under CR. In par-
ticular, genes differentially expressed with respect to at
least three of four long-lived models, as well as with
respect to at least one of the four CR contrasts were iden-
tified, which yielded 30 additional candidate genes (Fig.
8). Significantly overrepresented biological process gene
ontology terms among these genes included electron
transport, secondary metabolism, amine metabolism,
steroid biosynthesis, and establishment of localization (P
< 0.05). The cellular components endoplasmic reticulum,
microsome, membrane fraction and extracellular space
were also significantly overrepresented (P < 0.01). A wide
range of molecular function gene ontology terms were
Differential expression signature similarity matrix Figure 5
Differential expression signature similarity matrix. In the upper-right triangle region, dark red colors indicate high sim-
ilarity between signatures associated with two contrasts (indicated by row and column labels). This similarity is defined by 
Equation (1) in the Methods section. The binary coding in the lower-left triangle region indicates whether signatures associated 
with two contrasts exhibit a significant level of similarity. The statistical procedure used to evaluate similarity is described in the 
Methods section. Contrast pairs with significant similarity (P < 0.05) are coded dark red, while pairs with non-significant simi-
larity have no coloring.
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overrepresented, the most significant of which were
monooxygenase activity, heme binding, iron ion binding
and insulin-like growth factor binding (P < 0.01).
The expression level of flavin-containing monoxygenase 3
(Fmo3) was positively correlated with mean lifespan
among 21 BxD strains (rs = 0.410, see Fig. 9A). This corre-
lation was significant when taken alone (P = 0.033), but
not following p-value adjustment for multiple testing
among all 33 genes considered (P = 0.366). In addition to
Fmo3, five other genes listed in Figure 7 exhibited margin-
ally significant correlations prior to multiple testing
adjustment (Ero11b, Serpina12, Hes6, Cyp2f2 and
Cyp4a14) (0.063 < P < 0.108; see Fig. 9B–9F). In each
case, the relationship between baseline expression level
and mean lifespan was consistent with that expected
based on differential expression patterns in dwarf models
and under CR (compare Fig. 8 to Fig. 9).
Discussion
Comparative analysis of multiple microarray datasets may
provide insight not obtainable through analysis of any
Longevity-associated genes I Figure 6
Longevity-associated genes I. Listed genes are those that are differentially expressed with respect to each of four-long 
lived dwarf models (Snell, Ames, Little, GHR-KO). Each row corresponds to an individual candidate gene, while each column 
corresponds to one of the contrasts listed in Table 1. Red squares indicate significant upregulation, while green squares indi-
cate significant downregulation.
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one dataset individually. This study presented a side-by-
side comparison of microarray datasets generated from
more than ten different studies of mouse liver organs,
along with an analysis of each dataset using a consistent
statistical methodology. The results provide a comprehen-
sive view of how the effects of life-extending dwarf muta-
tions, caloric restriction (CR), CR mimetic compounds,
low fat diets, gender and aging are related at the level of
gene expression. Comparisons among these various
effects, based on expression patterns of more than 8500
genes, are of interest from multiple perspectives and shed
light on a range of issues related to mammalian aging
[e.g., see discussions in [16,19,23,24,33-35]]. A total of 43
candidate longevity-associated genes were identified
based upon common differential expression patterns
among four long-lived dwarf models, or between dwarf
models and CR treatments. Each gene was identified
across multiple independent experiments, and is therefore
Candidate gene expression versus mean lifespan I Figure 7
Candidate gene expression versus mean lifespan I. The expression level of nine candidate genes was examined among 
21 BxD mouse strains. Expression data was generated by Williams et al. [30] (GEO series GSE6621). Lifespans of BxD strains 
were assayed by Gelman et al. [31]. The dashed horizontal line indicates the average gene expression level for each gene, while 
the solid line represents the least-squares regression estimate. Individual plots are shown for (A) Hao3, (B) Sult2a2, (C) Spink3, 
(D) Socs2, (E) Mup4, (F) Igfals, (G) Lifr, (H) Igf1 and (I) Efgr. The spearman rank correlation between expression and mean 
lifespan is shown in the upper right corner of each plot.
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very unlikely to be a false positive identification. The set
of longevity-associated genes identified in this analysis
therefore provides well-supported targets for future exper-
imental investigation as well as potential clues for under-
standing the functional basis of lifespan extension in
mammalian systems.
The GHR-KO mutation was associated with much smaller
transcriptional effects than mutations carried by Snell,
Ames and Little mice. This result is surprising, particularly
since GHR-KO and Little mice both carry mutations that
specifically affect GH signaling. Little mice are GH defi-
cient because the pituitary is unresponsive to GHRH,
while GHR-KO mice have elevated GH levels and lack GH
receptor. Transcriptional changes associated with both
mutants should therefore reflect inhibition of GH signal-
ing and, on this basis, it might be expected that the lit and
GHR-KO mutations have similar effects on gene expres-
sion patterns. This was not the case, however, given that
500–600 genes were differentially expressed with respect
to Little mice, while fewer than 50 genes were differen-
tially expressed with respect to GHR-KO mice. This differ-
Longevity-associated genes II Figure 8
Longevity-associated genes II. Listed genes are those that are differentially expressed with respect to at least three of four 
long-lived dwarf models (Snell, Ames, Little, GHR-KO), and with respect to at least one of the four caloric restriction con-
trasts. Each row corresponds to an individual candidate gene, while each column corresponds to one of the contrasts listed in 
Table 1. Red squares indicate significant upregulation and green squares indicate significant downregulation.
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ence does not reflect sample size and statistical power
disparities between experiments (see Table 2), and more-
over, agrees with an earlier study that found very few
genes (10 of 2352) differentially expressed between GHR-
KO mice and normal controls [23]. This observation is
also consistent with phenotypic data, which indicate that
Little and GHR-KO mice exhibit dissimilar magnitudes of
lifespan extension [9,15], as well as differing developmen-
tal weight-gain patterns [15]. It is possible that some dis-
parity between differential expression signatures of GHR-
KO and Little mice can be attributed to technical differ-
ences in sample preparation and array hybridizations.
Another possibility is that the difference is due to levels of
circulating growth hormone, which is nearly absent in Lit-
tle mice and elevated in GHR-KO mice [9,15]. This differ-
ence would influence gene expression patterns in liver if
GH has systemic or local effects independent of the GH
receptor. These considerations suggest that, in compari-
son to other dwarf mutants, GHR-KO mice may provide a
more useful model for the purpose of elucidating the
Candidate gene expression versus mean lifespan II Figure 9
Candidate gene expression versus mean lifespan II. The expression level of six candidate genes was examined among 21 
BxD mouse strains (see Fig. 6 caption). The dashed horizontal line indicates the average gene expression level for each gene, 
while the solid line indicates the estimates least-squares regression estimate. Individual plots are shown for (A) Fmo3, (B) 
Ero11b, (C) Serpina12, (D) Hes6, (E) Cyp2f2 and (F) Cyp4a14. The spearman rank correlation between expression and mean 
lifespan is shown in the upper right corner of each plot.
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mechanisms of longevity extension in mammals. GHR-
KO mice exhibit lifespan extension that is comparable to
that associated with Snell, Ames and Little mice. However,
since the downstream transcriptional effects of the GHR-
KO mutation are much less extensive than those of other
long-lived models, understanding how this mutation con-
tributes to longevity extension may prove less difficult.
Dwarf mutations and CR both extend lifespan in mice,
but the degree to which this effect is mediated by common
mechanisms remains unclear [23-25]. With regard to
mouse liver tissue, this study reveals both similarities and
differences between the effects of dwarf mutations and
CR. The overall similarity between differential expression
signatures associated with dwarf mutations and CR is sig-
nificantly larger than expected on the basis of chance (Fig.
5). This is reflected by the 33 genes that exhibit parallel
differential expression patterns in most long-lived
mutants and under at least one CR treatment (Fig. 8). On
the other hand, results of this analysis suggest that dwarf
mutations have a much larger and more consistent effect
on IGF-I expression than CR treatments (as well as poten-
tial CR mimetic compounds). This result was surprising,
since several studies have shown that IGF-I expression and
protein levels decline under CR [36-38]. It was further sur-
prising that of the four CR treatments, IGF-I expression
was only decreased significantly when CR was applied to
dwarf mice (which already exhibit IGF-I deficiency).
Taken together, these results suggest that life-extending
dwarf mutations have mechanisms in common with CR,
but that IGF-I suppression may not necessarily be
included among these shared mechanisms. A limitation
related to this inference is that the effects of CR treatments
on expression patterns vary considerably among different
studies, depending on the duration of caloric restriction,
age at which necropsies are performed and the laboratory
in which CR is carried out (see Figs. 3 and 4). A robust
generalization regarding how the transcriptional effects of
dwarf mutations relate to those of CR would therefore
require even more data from CR mice than was analyzed
in the present study.
Candidate longevity-associated genes were identified
based on one of either two premises. The first premise is
that lifespan extension in Snell, Ames, Little and GHR-KO
mice is due to shared GH/IGF-I alterations, such that
genes exhibiting parallel transcriptional changes in all
four models are likely to play an important role in longev-
ity. The second premise is that longevity extension in
dwarf models and under CR is achieved through common
mechanisms, suggesting that genes with similar expres-
sion changes in multiple dwarf models and under CR are
potentially important for longevity. There is evidence in
favor of both of these premises, and both have been
endorsed in previous analyses [17,18,20,23]. It should be
noted, however, that since the functional basis of mam-
malian lifespan is not well understood, the validity of
each premise has not been established with certainty. Fur-
thermore, all data examined in this study were generated
from liver tissue. Liver tissue is the primary manufacturing
site of IGF-I, but it is nonetheless possible that expression
patterns in other tissues are of equal or greater importance
in determining longevity. For instance, fibroblasts of long-
lived mice are more stress-resistant than those of normal
controls, suggesting that dwarf mutations affect a wide
range of tissue and cell types [10,11]. In fact, reduced IGF-
I levels in circulation may be the main factor behind
extended lifespan in dwarf mice, such that with respect to
liver, the only expression change consequential for lon-
gevity determination is that of the IGF-I transcript. These
considerations should be weighed when evaluating the
potential role of candidate genes in determining lifespan
and rates of aging in mice and other mammalian species.
Only three genes were differentially expressed with respect
to all four long-lived dwarf models with corresponding
effects under at least one CR treatment (IGF-I, Igfals and
Lifr). Both Igf1 and Igfals have a well-documented role in
lifespan determination [39,40], but a potential role of
leukemia inhibitory factor receptor (Lifr) in longevity has
not been widely explored. Lifr expression was downregu-
lated at all ages in four long-lived dwarf models, by short-
term CR and by low-fat diet. Determining whether Lifr
downregulation in liver contributes to longevity extension
represents a difficult task, since Lifr is highly pleiotropic
and has been associated with a wide range of biological
effects. While there are several molecules that Lifr may
interact with [41-43], Lifr expression is a primary determi-
nant of cellular responsiveness to leukemia inhibitory fac-
tor (Lif) [44]. The Lif glycoprotein is a member of the IL-
6 type cytokine family and exhibits a wide range of effects
among different cell types. At a systemic level, excess Lif
has been associated with low body weight, hypermotility,
overgrowth of bone, calcification of several organs, loss of
spermatocytes in males and severe loss of adipose tissue
[44], and in the liver specifically, Lif has been found to
stimulate triglyceride secretion [45]. Interestingly, how-
ever, Lif(-/-) mutants have been found to develop nor-
mally and possess generally good health, although
pregnancy does not occur in females due to problems
with blastocyst implantation [46]. To some degree, inhi-
bition of Lif/Lifr signaling may be countered in long-lived
mice by down-regulation of Socs2 (suppressor of cytokine
signaling) [47,48], which was also down-regulated in all
four long-lived dwarf models. Declines in Lifr expression
may increase sensitivity to drug-induced liver disease [49],
which in general is contrary to the stress resistance charac-
teristics of long-lived mice [11], but is consistent with one
study that found decreased resistance to acetaminophen
toxicity in multiple dwarf strains [50].BMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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Fmo3 and Cyp2f2 were differentially expressed with
respect to most (3/4) long-lived dwarf models and also
under the majority (3/4) of CR treatments that were exam-
ined. In addition, the expression level of both genes varied
with mean lifespan among 21 BxD recombinant inbred
mouse strains in a direction consistent with differential
expression analyses. Since both genes are monooxygen-
ases with established roles in drug metabolism, their
expression in liver could mediate the life-extending effects
of dwarf-mutations and CR through similar mechanisms.
Fmo3 is a flavin containing monoxygenase for which
expression levels are elevated in long-lived dwarf mutants,
female mice, CR mice and mice treated with each of three
different CR mimetic compounds (metaformin, glipizide
and rosiglitazone). The Fmo3 gene has received consider-
able attention in studies of human populations, since it
exhibits extensive polymorphism among individuals and
may be a factor promoting differential drug response [51].
With regard to aging processes, a plausible hypothesis is
that elevated Fmo3 levels in liver contributes to extended
longevity by increasing stores of glutathione (GSH) and
glutathione-S-transferase (GST), which then leads to
enhanced resistance to oxidative stress. This hypothesis is
appealing, since Fmo3 has an important role in sulfoxida-
tion of methionine [52,53], and it has been found that
long-lived Ames mice exhibit elevated methionine metab-
olism [54], which may underlie increased GSH, GST and
oxidative stress resistance in long-lived models [54].
Cyp2f2 is a cytochrome P450 enzyme, and in contrast to
Fmo3, its expression was downregulated in long-lived and
CR mice. Several other cytochrome P450 enzymes exhib-
ited differential expression, with slightly less consistency,
among multiple long-lived models and under CR treat-
ments (Cyp4a14, Cyp2c38, Cyp2c39 and Cyp4a12b).
Although Cyp2f2 displayed the most consistent differen-
tial expression pattern, it is unlikely that Cyp2f2 would
have a unique role in mammalian aging apart from other
cytochrome P450 enzymes. Cytochrome P450 enzymes
are involved in xenobiotic detoxification and are catalysts
for a large number of metabolic reactions. It is unclear
how this system may influence aging in mammals, but
multiple P450 enzymes are also differentially expressed in
long-lived C. elegans daf-2 mutants, which has led to the
suggestion that P450 enzymes slow aging by reducing
damage generated from toxic compounds [55,56]. From
the standpoint of mammalian aging, it is of interest that
some P450 enzymes, including Cyp2f2, are regulated by
peroxisome proliferator-activated receptors (PPARs)
[57,58]. Cytochrome P450 enzymes may therefore be part
of a broader cellular response that has previously been
associated with longevity in long-lived and CR mice [59].
An interesting pattern is that, in many cases, P450 enzyme
expression changes in long-lived mice and under CR were
mirrored by expression differences in females relative to
males. In a comprehensive analysis of 41 cytochrome
P450 enzyme genes, it was found that 14 genes exhibited
this pattern to some degree (data not shown). This result
may be attributable to the role of GH as a factor regulating
cytochrome P450 expression [60].
The correlation structure of expression patterns among
genes may be as informative as differential expression
analyses but is often an underexploited aspect of microar-
ray datasets. Similarity among expression patterns across
many conditions can be used, for example, to make infer-
ences and generate testable hypotheses regarding interac-
tions between genes [61,62]. Along these lines, genes with
expression patterns among contrasts that closely corre-
sponded with those of the IGF-I transcript were identified
in this study. This analysis identified Snm1 (DNA cross-
link repair 1a; also called Dclre1a) as a potential IGF-I reg-
ulated or co-regulated gene (see Fig. 2 and additional file
2). The induction pattern of Snm1 is opposite that of IGF-
I across contrasts, such that its expression is increased in
proportion to IGF-I inhibition. Snm1(-/-)  mice have
reduced lifespan, which is primarily due to elevated mor-
tality from bacterial infection and cancer, suggesting that
Snm1 is a tumor suppressor with an immunological role
[63]. At the cellular level, overexpression of Snm1 in yeast
increases resistance to genotoxic stress agents that induce
DNA cross-links [64], and stem cells derived from Snm1(-
/-) mice are sensitive to the cross-linking agent mitomycin
C [65]. These results suggest that elevated Snm1 expres-
sion may be a causal factor underlying resistance to the
DNA-alkylating agent methyl methanesulfonate that has
previously been found in cell lines derived from long-
lived mice [10,11]. It would thus be worthwhile to evalu-
ate whether Snm1 expression is elevated in such cell lines
(as in hepatic tissue), and if so, whether these cells are
resistant to DNA cross-link inducing agents (e.g., nitrogen
mustard, cisplatin). Interestingly, recent studies report
that DNA repair mutations leading to accelerated senes-
cence phenotypes are, like long-lived dwarf mutations,
associated with IGF-I inhibition [66]. It is therefore sur-
prising that in long-lived and CR mice, IGF-I inhibition is
associated with elevated Snm1 expression, which may
enhance DNA repair and promote genomic stability.
The present study has demonstrated analytical approaches
for the comparative analysis of microarray datasets that
may have application in other contexts. Microarray analy-
ses based upon individual datasets often identify an
exceptionally large number of genes, which limits the util-
ity of microarray data as a tool for selecting candidates in
follow-up studies. Recently, however, public repositories
of high-quality microarray data have been established
[67,68], and statistical methods aimed at comparative
analysis of these resources continue to be developed [69-
72]. Increasingly, therefore, comparative analysis providesBMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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a feasible approach for filtering out false-positive identifi-
cations and identifying transcripts most consistently sup-
ported across multiple experiments. This yields a set of
candidate genes that is necessarily smaller and more trac-
table for subsequent experimental investigation, and
moreover, each identified gene is more likely to represent
a statistically significant finding. Furthermore, apart from
the identification of individual gene candidates, compari-
son of expression datasets provides unique insight into
genome-wide patterns among studies.
The maximum human lifespan is approximately twice as
large as the maximum chimpanzee lifespan [73], which is
more than ten times larger than the maximum mouse
lifespan [2]. The evolutionary lineage connecting humans
to chimpanzees to mouse may therefore represent a
remarkable instance of lifespan extension and delayed
rates of aging. Inhibition of IGF-I signaling is (at present)
the only known genetic manipulation that extends
lifespan in multiple species, so it is tempting to ask
whether this pathway has contributed to evolutionary
extension of lifespan within the mammalian lineage. It is
interesting to note that, contrary to longevity extension
via nearly all IGF-I signaling mutations, lifespan extension
in the mouse-chimp-human lineage has been accompa-
nied by an increase  in body size. This observation is
encouraging with regard to the possibility of developing
interventions that delay the onset of age-related disease in
humans without undesirable consequences (e.g., dwarf-
ism). Clarke et al. [74] used sequence data and dN/dS ratios
to identify mouse-chimp-human orthologs that exhibit
more rapid evolutionary change than expected based
upon neutral substitution models (i.e., positive selec-
tion). Supplemental data from their study provides no
indication of positive selection with respect to IGF-I, pro-
viding little indication that IGF-I sequence changes have
been consequential during human evolution. It is interest-
ing to note, however, that Dio1 (iodothyronine deiodi-
nase), which is downregulated in most dwarf mouse
strains and under CR (see Fig. 8), has been associated with
positive selection and accelerated evolution within the
mouse-chimp-human lineage (see supplemental data
from [74]). This is also the case for Papp-A (pregnancy
associated plasma protein A) [74], which was not identi-
fied in the present study, but is of importance since Papp-
A-KO mice exhibit diminished IGF-I bioactivity and
extended lifespan [75]. These results are suggestive, but
given the many phenotypic differences between mice,
chimpanzees and humans (besides lifespan), this evolu-
tionary criterion does not establish the functional signifi-
cance of Dio1, Papp-A or other positively selected genes.
These findings provide a useful reference point for future
experimental studies of long-lived dwarf mice and mam-
malian aging. It would be of interest, for example, to
determine whether genes identified in the present study
are differentially expressed with respect to other long-
lived mouse strains for which data is not currently availa-
ble. Similar gene expression changes may be found in liver
tissue of p66shc knockouts [76], IGF-IR knockouts [77],
Klotho transgenic mice [78] and Papp-A-KO mice [75],
since each of these long-lived models carry mutations that
also inhibit the IGF-I signaling pathway. Because these
mutations inhibit IGF-I signals at points further down-
stream than those considered in this study, expression
data generated from these models could be combined
with results of the present study to assemble a more com-
prehensive picture of hepatic IGF-I signaling. Since the
currently known life-extending mutations are maintained
on differing genetic backgrounds [1], evaluating potential
background effects on lifespan and gene expression pat-
terns will also be critical for elucidating hepatic IGF-1 sig-
naling pathways [79]. Ultimately, however, it is important
to develop a systemic model of GH/IGF-I signaling, with
further evaluation of the respective roles of IGF-I and GH
in extended longevity. IGF-I is manufactured in a wide
variety of tissue types, and in some cases IGF-I production
may be independent of GH signaling [80]. It is therefore
important to consider not only local effects of GH reduc-
tion on gene expression in liver, but also effects of GH/
IGF-I in other tissue types. Studies of long-lived C. elegans
mutants, for instance, have suggested that IGF-I signaling
in nervous tissue may be consequential in determining
lifespan [81]. It would therefore be useful to evaluate
whether genes identified in the present study are also dif-
ferentially expressed in non-hepatic tissues of Ames, Snell,
Little or GHR-KO mice.
Conclusion
Several mutations are known to increase longevity in
mouse, but most of these mutations are associated with
pleiotropic effects, which include traits that are undesira-
ble from a therapeutic perspective (e.g., dwarfism). A key
challenge in future work towards potential longevity-pro-
moting therapeutic compounds is to decouple the posi-
tive life-extending effects of IGF-I inhibition from
diminutions in growth and body size. Determining
whether this is a possibility requires a more complete
functional understanding of longevity extension in long-
lived mutant mouse models. The present study has taken
steps in this direction by presenting comparisons between
the transcriptional effects of dwarf mutations and those of
dietary treatments, gender and aging. Among other find-
ings, these comparisons reveal that lit/lit  and  GHR-KO
mutations exhibit transcriptional effects of surprisingly
different magnitude, transcriptional effects of CR (and
some CR mimetics) resemble aging more closely then
those of dwarf mutations, and that the transcriptional
effects of gender and lowfat diets overlap significantly
with those of dwarf mutations and CR. A total of 43 genesBMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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with the highest levels of support as longevity-associated
transcripts were identified in this context. The main value
of identified genes is the potential that, as putative down-
stream elements in the IGF-I signaling pathway, some
genes may be more directly (and functionally) involved in
longevity determination than upstream IGF-I signaling
components. Experimental studies focusing on identified
genes may therefore enhance our functional understand-
ing of how mutations affecting IGF-I signaling lead to
extended lifespan and deceleration of aging in mammals.
Methods
Gene expression datasets analyzed in this study were
selected from those available in the Gene Expression
Omnibus (GEO) and ArrayExpress depositories for
MIAME-compliant microarray data [67,68]. Expression
datasets were generated using one of three Affymetrix
microarray platforms (MG-U74A, MOE430A, 430 2.0).
Expression values were calculated by either the MAS 5.0
algorithm or Robust Multichip Average [82]. When raw
CEL files were available, MAS 5.0 generated datasets were
re-normalized using RMA.
Differential expression testing was performed using the
Limma linear modeling package available in the R Bio-
conductor software suite [83]. This approach fits a linear
model to expression values associated with each individ-
ual gene, and the distribution of sample residual variances
among all genes is used to stabilize the residual variance
estimates of individual genes by shrinkage towards a prior
value. This limits false-positive gene identifications aris-
ing from underestimated residual variances for datasets
with low levels of replication in each experimental treat-
ment. Separate linear model analyses were conducted for
contrast groups sharing the same superscript in Table 1.
Expression values were not combined, therefore, when
expression was assayed using different platforms or when
experiments were performed in different laboratories. For
each contrast, P-values were adjusted across genes using
the Benjamini-Hochberg method [84]. When multiple
contrasts were specified for a single dataset, the nested-F
test approach was used to evaluate the significance of
moderated t-statistics associated with each individual
contrast [83].
Longevity-associated genes were identified based on com-
mon differential expression patterns among contrasts
using criteria described in the Results section. The GOstats
R Bioconductor package was used evaluate whether partic-
ular gene ontology terms were overrepresented with
respect to identified genes [85]. The gene universe in each
test was defined as the 8525 probesets included in the
analysis, i.e., those that could be matched among the MG-
U74A, MOE430A and 430 2.0 Affymetrix platforms [85].
Differential expression signature similarity metric
A similarity measure was developed to compare gene
expression signatures associated with different contrasts.
This similarity is intuitive in terms of Venn diagrams,
where the similarity between two signatures is propor-
tional to the overlap between sets of genes differentially
expressed with respect to each contrast individually. This
notion was generalized in order to define a measure of
similarity that can be used for clustering signatures associ-
ated with different contrasts. Consider two signatures that
have been generated by two contrasts α and β. Using the
notations defined in Table 3, the signatures contain n+,+ +
n-,- genes with identical differential expression patterns,
n+,- + n-,+ genes with opposite differential expression pat-
terns, and n+,0  +  n0,+  +  n-,0  +  n0,-  genes differentially
expressed with respect to just one of the two contrasts.
Given these values, Equation (1) defines a measure of
similarity (s) between two different signatures, where 0 ≤
s ≤ 1.
There are several plausible similarity measures between
two different signatures. A main advantage of the similar-
ity measure defined by Equation (1) is that similarity not
increased by the n0,0  genes that are not differentially
expressed with respect to either contrast. Thus, emphasis
is placed only on the minority of genes that are differen-
s
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Table 3: Notations associated with Equation (1)
Contrast α
Upregulated Downregulated H0 not rejected
Contrast β Upregulated n+,+ n-,+ n0,+
Downregulated n+,- n-,- n0,-
H0 not rejected n+,0 n-,0 n0,0
The null hypothesis H0: µAi = µBi was evaluated for N genes with respect to contrasts α and β (see text). With respect to each contrast individually, 
genes are either upregulated, downregulated, or H0 is not rejected. With respect to both contrasts α and β, therefore, all N genes are classified into 
one of nine categories. The number of genes assigned to each category is indicated by the values of n given in the table.BMC Genomics 2007, 8:353 http://www.biomedcentral.com/1471-2164/8/353
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tially expressed. Additionally, the denominator of Equa-
tion (1) is configured such that two signatures may be
similar even if they differ greatly in the total number of
genes that are differentially expressed, provided that the
contrast associated with less differential expression yields
approximately  n+,+  +  n-,-  differentially expressed genes.
This is sensible in consideration of the fact that the
number of differentially expressed genes generated by a
given contrast depends on the sample sizes used in the
experimental treatments being compared. For signature
comparisons in the present study, the value n+,- + n-,+ was
negligible and therefore not included in Equation (1). If
n+,- + n-,+ had been large, however, it would have been
appropriate to add this term to the denominator of Equa-
tion (1) when evaluating similarity between signatures.
Differential expression signatures for each contrast listed
in Table 1 were compared using the similarity measure
defined by Equation (1). The distance between two signa-
tures was defined as 1 – s and a hierarchical cluster analy-
sis of signatures associated with the 31 contrasts specified
in Table 1 was performed (Fig. 4). Groups of signatures
were joined using the average distance method. This
yielded a dendrogram providing an indication of which
contrasts were associated with similar differential expres-
sion patterns.
Statistical evaluation of overlap between differential 
expression signatures
A statistical procedure was developed to evaluate whether
differential expression signatures associated with two dif-
ferent contrasts exhibited a significant level of similarity.
Among the 31 contrasts, the correspondence between all
31(31-1)/2 = 465 pairwise combinations of signatures
was evaluated. The procedure used is similar to that pro-
posed by Smid et al. [86]. The null hypothesis for this sta-
tistical test is that, for any two contrasts α  and β, the
probability that a gene is differentially expressed with
respect to contrast α is independent of the probability that
a gene is differentially expressed with respect to contrast β.
It should be noted that the three contrasts with a d super-
script in Table 1 were defined using a common control
treatment as a reference. It is thus expected a priori that dif-
ferential expression signatures of these three contrasts will
exhibit association beyond that stated by the null hypoth-
esis defined above. This is also true of the seven contrasts
carrying an h superscript in Table 1.
The value T defined below is proportional to s and serves
as the test statistic.
T = n+,+ + n-,-
A total of N genes are considered in the analysis. It is given
that   genes upregulated with respect to contrast α, 
genes downregulated with respect to contrast α,   genes
upregulated with respect to contrast β, and   genes
downregulated with respect to contrast β. Given these
quantities,   is the probability of upregulation with
respect to contrast α,   is the probability of downregu-
lation with respect to contrast α,   is the probability of
upregulation with respect to contrast β, and   is the
probability of downregulation with respect to contrast β.
Under the null hypothesis stated above,   is independ-
ent of   and   is independent of  . Conse-
quently, the probability that a gene is jointly upregulated
with respect to contrasts α and β is given by p1, while the
probability that a gene is jointly downregulated with
respect to contrasts α and β is given by p2.
Random variable X denotes the number of jointly upreg-
ulated genes among all N genes, and random variable Y
equals the number of jointly downregulated genes among
all N genes, such that T = X + Y. The distributions of X and
Y are binomial under the null hypothesis.
When Np1 and Np2 are large, P(X = x) and P(Y = y) and
their convolution T = X + Y are approximately Normal
under H0. When Np1 and Np2 are small, P(X = x) and P(Y
= y) and their convolution T = X + Y are approximately
Poisson under H0. The significance of observed T values
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for each pair of contrasts by comparison to either Normal
or Poisson cumulative distribution functions, depending
on the magnitude of Np1 and Np2. This test was carried out
for all pairwise combinations of the 31 contrasts evalu-
ated, yielding a total of 31(31-1)/2 = 465 p-values. All p-
values were confirmed by simulation analyses. To control
for multiple testing, p-values were adjusted using the Ben-
jamini-Hochberg method.
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